IP Verse

Pvrig Polypeptides And Methods Of Treatment - EP3259597

The patent EP3259597 was granted to Compugen on Apr 6, 2022. The application was originally filed on Feb 19, 2016 under application number EP16711051A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3259597

COMPUGEN
Application Number
EP16711051A
Filing Date
Feb 19, 2016
Status
Granted And Under Opposition
Mar 4, 2022
Grant Date
Apr 6, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GLAXOSMITHKLINEJan 5, 2023SUENADMISSIBLE

Patent Citations (31) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0338841
DESCRIPTIONEP1176195
DESCRIPTIONUS2004110704
DESCRIPTIONUS3773919
DESCRIPTIONUS4399216
DESCRIPTIONUS4485045
DESCRIPTIONUS4544545
DESCRIPTIONUS4634665
DESCRIPTIONUS5013556
DESCRIPTIONUS5179017
DESCRIPTIONUS5624821
DESCRIPTIONUS5648260
DESCRIPTIONUS5869046
DESCRIPTIONUS6121022
DESCRIPTIONUS6194551
DESCRIPTIONUS6277375
DESCRIPTIONUS7371826
DESCRIPTIONUS8883973
DESCRIPTIONWO0042072
DESCRIPTIONWO03035835
DESCRIPTIONWO2004091658
DESCRIPTIONWO2009126688
DESCRIPTIONWO8704462
DESCRIPTIONWO8901036
DESCRIPTIONWO9429351
DESCRIPTIONWO9738731
DESCRIPTIONWO9954342
INTERNATIONAL-SEARCH-REPORTWO0052151
INTERNATIONAL-SEARCH-REPORTWO2004058805
INTERNATIONAL-SEARCH-REPORTWO2013184912
OPPOSITIONWO2017041004

Non-Patent Literature (NPL) Citations (33) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BO ET AL., BIOINFORMATICS, (2010), vol. 26, no. 4, pages 493 - 500-
DESCRIPTION- CHAN CA; CARTER PJ, NATURE REV IMMUNOL, (2010), vol. 10, pages 301 - 316-
DESCRIPTION- CLIN DEV IMMUNOL., (2012), page 720803-
DESCRIPTION- CLIN IMMUNOL., (201108), vol. 140, no. 2, pages 167 - 176-
DESCRIPTION- DRAKE; KLAKAMP, JOURNAL OF IMMUNOL METHODS, (2007), vol. 318, pages 147 - 152-
DESCRIPTION- EPSTEIN ET AL., PROC NATL ACAD SCI USA, (1985), vol. 82, page 3688-
DESCRIPTION- "Gene Expression Technology", GOEDDEL, Methods in Enzymology, ACADEMIC PRESS, (1990), vol. 185-
DESCRIPTION- HWANG ET AL., PROC NATL ACAD SCI USA, (1980), vol. 77, page 4030-
DESCRIPTION- JEFFERIS ET AL., IMMUNOL LETT, (2002), vol. 82, pages 57 - 65-
DESCRIPTION- MORGAN ET AL., SCIENCE, (2006), vol. 314, pages 126 - 129-
DESCRIPTION- NOA STANIETSKY, JOURNAL OF IMMUNOLOGY, vol. 106, no. 42, pages 17858 - 17863-
DESCRIPTION- R. J. KAUFMAN; P. A. SHARP, MOL. BIOL., (1982), vol. 159, pages 601 - 621-
DESCRIPTION- ROBERT J JOHNSTON, CANCER CELL, (20141208), vol. 26, no. 6, pages 923 - 937-
DESCRIPTION- SHIELDS, R. L. ET AL., J BIOL. CHEM., (2001), vol. 276, pages 6591 - 6604-
DESCRIPTION- SHIELDS, R. L. ET AL., J BIOL. CHEM., (2002), vol. 277, pages 26733 - 26740-
DESCRIPTION- TAKEBE, Y. ET AL., MOL. CELL. BIOL., (1988), vol. 8, pages 466 - 472-
DESCRIPTION- TARENTINO, A. L. ET AL., BIOCHEM., (1975), vol. 14, pages 5516 - 5523-
DESCRIPTION- TRAPNELL ET AL., NAT BIOTECHNOL., (201005), vol. 28, no. 5, pages 511 - 515-
DESCRIPTION- UMANA ET AL., NAT. BIOTECH., (1999), vol. 17, pages 176 - 180-
DESCRIPTION- URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, pages 4216 - 4220-
DESCRIPTION- YAMANE-OHNUKI ET AL., BIOTECHNOL BIOENG, (2004), vol. 87, pages 614 - 622-
DESCRIPTION- WANG, "Immune Suppression by Tumor Specific CD4+ Regulatory T cells in Cancer", SEMIN. CANCER. BIOL., (2006), vol. 16, doi:doi:10.1016/j.semcancer.2005.07.009, pages 73 - 79, XP024908039
DESCRIPTION- GREENWALD ET AL., "The B7 Family Revisited", ANN. REV. IMMUNOL., (2005), vol. 23, doi:doi:10.1146/annurev.immunol.23.021704.115611, pages 515 - 548, XP002481408
DESCRIPTION- WATTS, "TNF/TNFR Family Members in Co-stimulation of T Cell Responses", ANN. REV. IMMUNOL., (2005), vol. 23, doi:doi:10.1146/annurev.immunol.23.021704.115839, pages 23 - 68, XP008051583
DESCRIPTION- SADUM ET AL., "Immune Signatures of Murine and Human Cancers Reveal Unique Mechanisms of Tumor Escape and New Targets for Cancer Immunotherapy", CLIN. CANC. RES., (2007), vol. 13, no. 13, doi:doi:10.1158/1078-0432.CCR-07-0016, pages 4016 - 4025, XP055248327
INTERNATIONAL-SEARCH-REPORT- Gene Id, "PVRIG antibody -middle region Rabbit Polyclonal Antibody Catalog # AI13083 Specification PVRIG antibody -middle region -Product Information Application WB Primary Accession Q6DKI7 Other Accession NM_024070, NP_076975 Reactivity Human Predicted Human Host Rabbit Clonality Polyclonal Calculated MW 34k", Physiol. Genomics, (20060101), pages 201 - 218, URL: http://www.funakoshi.co.jp/data/datasheet/ABG/AI13083.pdf, XP055273924 [A] 1-16-
INTERNATIONAL-SEARCH-REPORT- ZHU YUWEN ET AL, "Identification of CD112R as a novel checkpoint for human T cells", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIV. PRESS, NEW YORK, NY, USA, (20160208), vol. 213, no. 2, ISSN 1540-9538, pages 167 - 176, XP009190107 [XP] 1-16 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- GALIT ROTMAN ET AL, "Identification of novel immune checkpoints as targets for cancer immunotherapy", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, (20131107), vol. 1, no. Suppl 1, doi:10.1186/2051-1426-1-S1-P135, ISSN 2051-1426, page P135, XP021167082 [A] 1-16
OPPOSITION- BROWN et al., "Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1", J Immunol, (20030201), vol. 170, no. 3, pages 1257 - 1266, XP002973918-
OPPOSITION- QUINONES et al., "2205 High-Throughput Cellular Assays Using A Well-Less Plate Format", Annual Meeting of the American Society for Cell Biology, (20111207), XP093014465-
OPPOSITION- Quinones, Et Al., "High-throughput cellular assays using a well-less plate format", Poster abstract no. 2205 (New Technologies and Frontiers), 2011 American Society for Cell Biology (ASCB) Annual Meeting, Denver , CO, (20111203), pages 1 - 3, Poster abstract no. 2205 (New Technologies and Frontiers), 2011 American Society for Cell Biology (ASCB) Annual Meeting, Denver , CO, (20201109), XP055748047-
OPPOSITION- ZHU et al., "Identification of CD 112R as a novel checkpoint for human T cells", JOURNAL OF EXPERIMENTAL MEDICINE, NEW YORK, NY, USA, (20160208), vol. 213, no. 2, doi:10.1084/jem.20150785, pages 167 - 176, XP055314642
OPPOSITION- WANG et al., "In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates", Cancer Immunol Res, (20140901), vol. 2, no. 9, doi:10.1158/2326-6066.CIR-14-0040, pages 846 - 856, XP055563054

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents